| meta-analysis | Q815382 |
| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | Bin Zhao | |
| Hong Zhao | |||
| Hao Weng | |||
| Hongli Zhao | |||
| Jiaxin Zhao | |||
| Liyuan Guo | |||
| P2860 | cites work | Expression of CXCR4 indicates poor prognosis in patients with clear cell carcinoma of the ovary | Q82953223 |
| Expression of CXCL12 and its receptor CXCR4 in esophageal squamous cell carcinoma | Q82966745 | ||
| Chemokine receptor CXCR4 expression is correlated with VEGF expression and poor survival in soft-tissue sarcoma | Q83082910 | ||
| Expression of chemokine CXCL12 and its receptor CXCR4 in human epithelial ovarian cancer: an independent prognostic factor for tumor progression | Q83187267 | ||
| CXCR4 expression in patients with high-risk locally advanced renal cell carcinoma can independently predict increased risk of disease progression and poor overall survival | Q83797990 | ||
| The expression of CXCL12 and CXCR4 in gastric cancer and their correlation to lymph node metastasis | Q84239888 | ||
| Expression of the chemokine receptor CXCR4 correlates with a favorable prognosis in patients with adenocarcinoma of the lung | Q84487244 | ||
| Intratumoural level of SDF-1 correlates with survival in head and neck squamous cell carcinoma | Q84761178 | ||
| Chemokine receptor CXCR4 level in primary tumors independently predicts outcome for patients with locally advanced breast cancer | Q84857707 | ||
| High expression of CXCR4 and CXCR7 predicts poor survival in gallbladder cancer | Q85070128 | ||
| Expression of CXCR4 is an independent prognostic factor for overall survival and progression-free survival in patients with myelodysplastic syndrome | Q85776048 | ||
| Low expression of microRNA-126 is associated with poor prognosis in colorectal cancer | Q87302004 | ||
| The expressions of MIF and CXCR4 protein in tumor microenvironment are adverse prognostic factors in patients with esophageal squamous cell carcinoma. | Q36758659 | ||
| The molecular and clinicopathologic characteristics of bilateral breast cancer | Q37147757 | ||
| New insights on the role of CXCR4 in cancer metastasis | Q37181856 | ||
| High expression of CXCR4 may predict poor survival in resected pancreatic adenocarcinoma | Q37222638 | ||
| The influence of tumor-host interactions in the stromal cell-derived factor-1/CXCR4 ligand/receptor axis in determining metastatic risk in breast cancer | Q37257112 | ||
| Translating an Antagonist of Chemokine Receptor CXCR4: from bench to bedside | Q37352422 | ||
| Nuclear localization of CXCR4 determines prognosis for colorectal cancer patients | Q37456485 | ||
| Expression of CXCR4 and breast cancer prognosis: a systematic review and meta-analysis | Q37547939 | ||
| A review on CXCR4/CXCL12 axis in oncology: no place to hide. | Q38017493 | ||
| Expression and prognostic significance of a comprehensive epithelial-mesenchymal transition gene set in renal cell carcinoma. | Q38312774 | ||
| Correlation between Chemokine Receptor CXCR4 Expression and Prognostic Factors in Patients with Prostate Cancer | Q38776802 | ||
| CXCR4 heterogeneous expression in esophageal squamous cell cancer and stronger metastatic potential with CXCR4-positive cancer cells | Q39131152 | ||
| Chemokine receptor CXCR4 expression, function, and clinical implications in gastric cancer | Q39894421 | ||
| Overexpression of both CXC chemokine receptor 4 and vascular endothelial growth factor proteins predicts early distant relapse in stage II-III colorectal cancer patients | Q40283597 | ||
| Expression of CXCR4 and its down-regulation by IFN-gamma in head and neck squamous cell carcinoma | Q40429792 | ||
| The clinicopathological significance of the expression of CXCR4 protein in oral squamous cell carcinoma. | Q40544421 | ||
| Relation between CXCR-4 expression, Flt3 mutations, and unfavorable prognosis of adult acute myeloid leukemia | Q40571705 | ||
| High chemokine receptor CXCR4 level in triple negative breast cancer specimens predicts poor clinical outcome | Q42454953 | ||
| Prognostic significance of CXCR-4 expression in oral squamous cell carcinoma | Q43883998 | ||
| The prognostic value of CXCR4 in acute myeloid leukemia | Q44237699 | ||
| Cytoplasmic CXCR4 high-expression exhibits distinct poor clinicopathological characteristics and predicts poor prognosis in triple-negative breast cancer | Q44293775 | ||
| A prognostic model comprising pT stage, N status, and the chemokine receptors CXCR4 and CXCR7 powerfully predicts outcome in neoadjuvant resistant rectal cancer patients | Q44412713 | ||
| Association of CXC chemokine receptor type 4 expression and clinicopathologic features in human vulvar cancer | Q44515542 | ||
| Concomitant overexpression of EGFR and CXCR4 is associated with worse prognosis in a new molecular subtype of non-small cell lung cancer | Q44678783 | ||
| Prognostic value of CXCR4 expression in patients with clear cell renal cell carcinoma | Q45199842 | ||
| Relationships between levels of CXCR4 and VEGF and blood-borne metastasis and survival in patients with osteosarcoma | Q45752215 | ||
| Prognostic impact of CXCR4 and CXCR7 expression in pancreatic adenocarcinoma | Q45815251 | ||
| Overexpression of CXCR4 in primary tumor of patients with HER-2 negative breast cancer was predictive of a poor disease-free survival: a validation study. | Q45931852 | ||
| Elevated chemokine receptor CXCR4 expression in primary tumors following neoadjuvant chemotherapy predicts poor outcomes for patients with locally advanced breast cancer (LABC). | Q46757098 | ||
| Chemokine receptor CXCR4 and early-stage non-small cell lung cancer: pattern of expression and correlation with outcome | Q47917544 | ||
| CXCR4 is a good survival prognostic indicator in multiple myeloma patients | Q48016232 | ||
| Close correlation between CXCR4 and VEGF expression and their prognostic implications in nasopharyngeal carcinoma. | Q48022968 | ||
| CXCR4 expression in early breast cancer and risk of distant recurrence | Q48398507 | ||
| Expression of chemokine receptors predicts the site of metastatic relapse in patients with axillary node positive primary breast cancer | Q48575675 | ||
| CXCR4 overexpression is associated with poor outcome in females diagnosed with stage IV non-small cell lung cancer. | Q51457342 | ||
| The expression of CXCR4 and its relationship with matrix metalloproteinase-9/vascular endothelial growth factor in esophageal squamous cell cancer | Q51742979 | ||
| CXCL12 and CXCR4 in adenocarcinoma of the lung: association with metastasis and survival. | Q51788497 | ||
| Clinicopathological and prognostic significance of chemokine receptor CXCR4 overexpression in patients with esophageal cancer: a meta-analysis. | Q53132108 | ||
| The chemokine receptor CXCR4 as a novel independent prognostic marker for node-positive breast cancer patients. | Q53175932 | ||
| CXCR4 is a prognostic marker in acute myelogenous leukemia. | Q53607339 | ||
| The role of CXCR4 receptor expression in breast cancer: a large tissue microarray study. | Q53644477 | ||
| High level of CXCR4 in triple-negative breast cancer specimens associated with a poor clinical outcome. | Q54415229 | ||
| Stromal CXCR4 and CXCL12 expression is associated with distant recurrence and poor prognosis in rectal cancer after chemoradiotherapy. | Q54440237 | ||
| Chemokine receptor CXCR4 overexpression predicts recurrence for hormone receptor-positive, node-negative breast cancer patients. | Q54665075 | ||
| Chemokine receptor CXCR4 expression in colorectal cancer patients increases the risk for recurrence and for poor survival. | Q54669043 | ||
| The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration | Q21092360 | ||
| Global cancer statistics | Q22241238 | ||
| CXC chemokine receptor 4 is a cell surface receptor for extracellular ubiquitin | Q24302660 | ||
| VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche | Q24600542 | ||
| Expression of chemokine receptor CXCR4 in nasopharyngeal carcinoma: pattern of expression and correlation with clinical outcome | Q24814632 | ||
| Operating characteristics of a rank correlation test for publication bias | Q27860653 | ||
| Measuring inconsistency in meta-analyses | Q27860655 | ||
| Meta-analysis in clinical trials | Q27860779 | ||
| Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses | Q28131633 | ||
| Practical methods for incorporating summary time-to-event data into meta-analysis | Q28131754 | ||
| CXCL12/SDF1 expression by breast cancers is an independent prognostic marker of disease-free and overall survival | Q28253569 | ||
| Genomic organization and promoter characterization of human CXCR4 gene | Q28271622 | ||
| CXCR4 expression on circulating pan-cytokeratin positive cells is associated with survival in patients with advanced non-small cell lung cancer | Q30439235 | ||
| Expression of chemokine receptor CXCR4 in esophageal squamous cell and adenocarcinoma | Q33266942 | ||
| CXC chemokine receptor 4 expression, CXC chemokine receptor 4 activation, and wild-type nucleophosmin are independently associated with unfavorable prognosis in patients with acute myeloid leukemia | Q33410331 | ||
| Chemokine receptor CXCR4 expression in hepatocellular carcinoma patients increases the risk of bone metastases and poor survival | Q33464680 | ||
| High CXC chemokine receptor 4 expression is an adverse prognostic factor in patients with clear-cell renal cell carcinoma | Q33555276 | ||
| Correlation effect of EGFR and CXCR4 and CCR7 chemokine receptors in predicting breast cancer metastasis and prognosis | Q33751824 | ||
| Persistent CXCR4 expression after preoperative chemoradiotherapy predicts early recurrence and poor prognosis in esophageal cancer | Q33868710 | ||
| Overexpression of CXCR4 is significantly associated with cisplatin-based chemotherapy resistance and can be a prognostic factor in epithelial ovarian cancer | Q34179827 | ||
| The influence of transforming growth factor-α, cyclooxygenase-2, matrix metalloproteinase (MMP)-7, MMP-9 and CXCR4 proteins involved in epithelial-mesenchymal transition on overall survival of patients with gastric cancer | Q34274752 | ||
| Cytokine patterns in patients with cancer: a systematic review. | Q34342581 | ||
| Small molecule inhibitors of CXCR4. | Q34574987 | ||
| Upregulated expression of C-X-C chemokine receptor 4 is an independent prognostic predictor for patients with gastric cancer | Q34927102 | ||
| The prognostic value of CXCR4 in ovarian cancer: a meta-analysis | Q35127922 | ||
| The chemokine, CXCL12, is an independent predictor of poor survival in ovarian cancer | Q35858991 | ||
| CXCR4-SDF-1 signalling, locomotion, chemotaxis and adhesion | Q35875566 | ||
| Co-expression of CXCR4 and CD133 proteins is associated with poor prognosis in stage II-III colon cancer patients | Q36225000 | ||
| Significance of CXCR4, phosphorylated STAT3 and VEGF-A expression in resected non-small cell lung cancer | Q36230718 | ||
| High expression of CXCR4, CXCR7 and SDF-1 predicts poor survival in renal cell carcinoma | Q36444607 | ||
| In ovarian cancer the prognostic influence of HER2/neu is not dependent on the CXCR4/SDF-1 signalling pathway. | Q36609813 | ||
| CXCR4 Expression Predicts Patient Outcome and Recurrence Patterns after Hepatic Resection for Colorectal Liver Metastases | Q57823384 | ||
| Prognostic value of the chemokine receptor CXCR4 and epithelial-to-mesenchymal transition in patients with squamous cell carcinoma of the mobile tongue | Q60641633 | ||
| Clinical significance of CXCR3 and CXCR4 expression in primary melanoma | Q62083291 | ||
| Concomitant CXCR4 and CXCR7 Expression Predicts Poor Prognosis in Renal Cancer | Q63247785 | ||
| Histomorphologic parameters and CXCR4 mRNA and protein expression in sentinel node melanoma metastasis are correlated to clinical outcome | Q63247792 | ||
| CXC chemokine receptor 4 is expressed in uveal malignant melanoma and correlates with the epithelioid-mixed cell type | Q63247797 | ||
| Expression of CXCR4 Predicts Poor Prognosis in Patients with Malignant Melanoma | Q63247804 | ||
| Association of CXCR4 and CCR7 chemokine receptor expression and lymph node metastasis in human cervical cancer | Q79219726 | ||
| Overexpression of CXCR4 predicts adverse overall and event-free survival in patients with unmutated FLT3 acute myeloid leukemia with normal karyotype | Q79812196 | ||
| Expression of growth factor and chemokine receptors: new insights in the biology of inflammatory breast cancer | Q79918235 | ||
| Prognostic implications of the nuclear localization of Y-box-binding protein-1 and CXCR4 expression in ovarian cancer: their correlation with activated Akt, LRP/MVP and P-glycoprotein expression | Q80216629 | ||
| Elevated levels of chemokine receptor CXCR4 in HER-2 negative breast cancer specimens predict recurrence | Q80489355 | ||
| Chemokine receptor CXCR4 expression and prognosis in patients with metastatic prostate cancer | Q80506644 | ||
| CXCR4 membrane expression in node-negative breast cancer | Q80974534 | ||
| Expression of chemokine receptors in human gastric cancer | Q81708351 | ||
| Tumor-cell homing to lymph nodes and bone marrow and CXCR4 expression in esophageal cancer | Q82040938 | ||
| P275 | copyright license | Creative Commons Attribution 2.5 Generic | Q18810333 |
| P433 | issue | 7 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | C-X-C motif chemokine receptor 4 | Q415718 |
| meta-analysis | Q815382 | ||
| neoplasm | Q1216998 | ||
| P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
| P304 | page(s) | 5022-40 | |
| P577 | publication date | 2015-03-10 | |
| P1433 | published in | Oncotarget | Q1573155 |
| P1476 | title | CXCR4 over-expression and survival in cancer: a system review and meta-analysis | |
| P478 | volume | 6 |
| Q42545669 | (68)Ga-Pentixafor-PET/CT for Imaging of Chemokine Receptor 4 Expression in Glioblastoma. |
| Q56763230 | A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators |
| Q38392841 | A Randomized, Open-Label Phase 2 Study of the CXCR4 Inhibitor LY2510924 in Combination with Sunitinib Versus Sunitinib Alone in Patients with Metastatic Renal Cell Carcinoma (RCC). |
| Q98159123 | A new class of PentixaFor- and PentixaTher-based theranostic agents with enhanced CXCR4-targeting efficiency |
| Q33747260 | A novel CXCR4-targeted near-infrared (NIR) fluorescent probe (Peptide R-NIR750) specifically detects CXCR4 expressing tumors |
| Q46439057 | ACKR3 expression on diffuse large B cell lymphoma is required for tumor spreading and tissue infiltration. |
| Q41189441 | An unusual type of myeloid sarcoma localization following myelofibrosis: A case report and literature review. |
| Q48206047 | Application of EGFR inhibitor reduces circulating tumor cells during transcatheter arterial embolization. |
| Q41708619 | Beclin 1 and LC3 as predictive biomarkers for metastatic colorectal carcinoma |
| Q37420781 | CXCL12 retargeting of an adenovirus vector to cancer cells using a bispecific adapter |
| Q49894726 | CXCL12-CXCR4 axis in feline mammary carcinoma |
| Q50277689 | CXCR4 Expression is Associated with Poor Prognosis in Patients with Esophageal Squamous Cell Carcinoma |
| Q95273130 | CXCR4 and JUNB double-positive disseminated tumor cells are detected frequently in breast cancer patients at primary diagnosis |
| Q63473694 | CXCR4 and its ligand CXCL12 display opposite expression profiles in feline mammary metastatic disease, with the exception of HER2-overexpressing tumors |
| Q35918942 | CXCR4 silencing inhibits invasion and migration of human laryngeal cancer Hep-2 cells |
| Q93048437 | CXCR4-Directed Imaging in Solid Tumors |
| Q88914214 | CXCR4-mediated osteosarcoma growth and pulmonary metastasis is suppressed by MicroRNA-613 |
| Q52668188 | CXCR4: A new player in vestibular schwannoma pathogenesis. |
| Q48172475 | Chemokine receptor CXCR7 is an independent prognostic biomarker in glioblastoma |
| Q37375733 | Chloroquine-Containing HPMA Copolymers as Polymeric Inhibitors of Cancer Cell Migration Mediated by the CXCR4/SDF-1 Chemokine Axis |
| Q38657644 | Chloroquine-Modified Hydroxyethyl Starch as a Polymeric Drug for Cancer Therapy |
| Q47737291 | Clinical significance of chemokine receptor CXCR4 and mammalian target of rapamycin (mTOR) expression in patients with diffuse large B-cell lymphoma |
| Q47729841 | Conjugate Polyplexes with Anti-Invasive Properties and Improved siRNA Delivery In Vivo |
| Q60909030 | Context-dependent roles of MDMX (MDM4) and MDM2 in breast cancer proliferation and circulating tumor cells |
| Q37045471 | Delivery of miR-200c Mimic with Poly(amido amine) CXCR4 Antagonists for Combined Inhibition of Cholangiocarcinoma Cell Invasiveness |
| Q64100423 | Different somatostatin and CXCR4 chemokine receptor expression in gastroenteropancreatic neuroendocrine neoplasms depending on their origin |
| Q91756279 | Differential gene expression in growth factors, epithelial mesenchymal transition and chemotaxis in the diffuse type compared with the intestinal type of gastric cancer |
| Q52562407 | Differential somatostatin, CXCR4 chemokine and endothelin A receptor expression in WHO grade I-IV astrocytic brain tumors. |
| Q46246670 | Distinct mobilization of leukocytes and hematopoietic stem cells by CXCR4 peptide antagonist LY2510924 and monoclonal antibody LY2624587. |
| Q37362728 | Expression and prognostic significance of CCL11/CCR3 in glioblastoma |
| Q89821179 | Fatal adverse events associated with programmed cell death protein 1 or programmed cell death-ligand 1 monotherapy in cancer |
| Q51248673 | Fatal attractions? Correlations of CXCL12-CXCR4-CXCR7 expression with disease progression in melanoma and Kaposi sarcoma. |
| Q52431058 | Genetic variation of CXCR4 and risk of coronary artery disease: epidemiological study and functional validation of CRISPR/Cas9 system. |
| Q38890114 | HMGB1 overexpression as a prognostic factor for survival in cancer: a meta-analysis and systematic review |
| Q55396735 | High co-expression of the SDF1/CXCR4 axis in hepatocarcinoma cells is regulated by AnnexinA7 in vitro and in vivo. |
| Q36413509 | Host genotype and tumor phenotype of chemokine decoy receptors integrally affect breast cancer relapse |
| Q37295663 | IFN-α potentiates the direct and immune-mediated antitumor effects of epigenetic drugs on both metastatic and stem cells of colorectal cancer |
| Q92738058 | Identification of key genes in osteosarcoma by meta‑analysis of gene expression microarray |
| Q47138737 | Incidence and risk of hematologic toxicities in cancer patients treated with regorafenib |
| Q45800216 | Incidence and risk of regorafenib-induced hepatotoxicity |
| Q65001384 | Invasive potential of hepatocellular carcinoma is enhanced by loss of selenium-binding protein 1 and subsequent upregulation of CXCR4. |
| Q55000995 | Isolated metastasis of an EGFR-L858R-mutated NSCLC of the meninges: the potential impact of CXCL12/CXCR4 axis in EGFRmut NSCLC in diagnosis, follow-up and treatment. |
| Q91736452 | LINC00922 Accelerates the Proliferation, Migration and Invasion of Lung Cancer Via the miRNA-204/CXCR4 Axis |
| Q39036560 | Long Non-Coding RNA MALAT1 Interacts With miR-204 to Modulate Human Hilar Cholangiocarcinoma Proliferation, Migration, and Invasion by Targeting CXCR4. |
| Q55085420 | Long non-coding RNA LSINCT5 promotes ovarian cancer cell proliferation, migration and invasion by disrupting the CXCL12/CXCR4 signalling axis. |
| Q58798205 | Making Sense of Pharmacology: Inverse Agonism and Functional Selectivity |
| Q49401185 | Mechanisms by which CXCR4/CXCL12 cause metastatic behavior in pancreatic cancer |
| Q37645010 | MicroRNA-126 inhibits colon cancer cell proliferation and invasion by targeting the chemokine (C-X-C motif) receptor 4 and Ras homolog gene family, member A, signaling pathway |
| Q47386839 | Onbaekwon Suppresses Colon Cancer Cell Invasion by Inhibiting Expression of the CXC Chemokine Receptor 4. |
| Q38808628 | Oncogenic roles and drug target of CXCR4/CXCL12 axis in lung cancer and cancer stem cell |
| Q37390708 | Pharmacological targeting of CXCL12/CXCR4 signaling in prostate cancer bone metastasis |
| Q89735524 | Preparation Of Nanobubbles Modified With A Small-Molecule CXCR4 Antagonist For Targeted Drug Delivery To Tumors And Enhanced Ultrasound Molecular Imaging |
| Q49229304 | Primary tumor-associated expression of CXCR4 predicts formation of local and systemic recurrency in head and neck squamous cell carcinoma. |
| Q33639397 | Prognostic and predictive value of circulating tumor cells and CXCR4 expression as biomarkers for a CXCR4 peptide antagonist in combination with carboplatin-etoposide in small cell lung cancer: exploratory analysis of a phase II study |
| Q91689974 | Prospective non-invasive evaluation of CXCR4 expression for the diagnosis of MALT lymphoma using [68Ga]Ga-Pentixafor-PET/MRI |
| Q49810281 | Quercetin Inhibits Breast Cancer Stem Cells via Downregulation of Aldehyde Dehydrogenase 1A1 (ALDH1A1), Chemokine Receptor Type 4 (CXCR4), Mucin 1 (MUC1), and Epithelial Cell Adhesion Molecule (EpCAM). |
| Q47697210 | RING finger protein 113A regulates C-X-C chemokine receptor type 4 stability and signaling |
| Q92782751 | Radiation-induced alterations in immunogenicity of a murine pancreatic ductal adenocarcinoma cell line |
| Q52624081 | SDF-1/CXCR4 expression in head and neck cancer and outcome after postoperative radiochemotherapy. |
| Q47100529 | Screening of cancer tissue arrays identifies CXCR4 on adrenocortical carcinoma: correlates with expression and quantification on metastases using 64Cu-plerixafor PET. |
| Q94562089 | Selective delivery of T22-PE24-H6 to CXCR4+ diffuse large B-cell lymphoma cells leads to wide therapeutic index in a disseminated mouse model |
| Q47146848 | Serum SDF-1 levels are a reliable diagnostic marker of feline mammary carcinoma, discriminating HER2-overexpressing tumors from other subtypes |
| Q47135284 | Somatostatin and CXCR4 chemokine receptor expression in hepatocellular and cholangiocellular carcinomas: tumor capillaries as promising targets |
| Q90748414 | Somatostatin and CXCR4 expression patterns in adenocarcinoma and squamous cell carcinoma of the lung relative to small cell lung cancer |
| Q37140477 | Targeted positron emission tomography imaging of CXCR4 expression in patients with acute myeloid leukemia |
| Q47850217 | Targeting CXCL12/CXCR4 Axis in Tumor Immunotherapy |
| Q89700528 | Targeting the CXCR4/CXCL12 axis with the peptide antagonist E5 to inhibit breast tumor progression |
| Q104111188 | The G protein coupled receptor CXCR4 designed by the QTY code becomes more hydrophilic and retains cell signaling activity |
| Q97426733 | Tumor dormancy in bone |
| Q33784472 | Using nanoBRET and CRISPR/Cas9 to monitor proximity to a genome-edited protein in real-time |
| Q41114242 | [177Lu]pentixather: Comprehensive Preclinical Characterization of a First CXCR4-directed Endoradiotherapeutic Agent. |
| Q93065291 | [68Ga]-Pentixafor PET/CT for CXCR4-Mediated Imaging of Vestibular Schwannomas |
| Q47099762 | [68Ga]pentixafor for CXCR4 imaging in a PC-3 prostate cancer xenograft model - comparison with [18F]FDG PET/CT, MRI and ex vivo receptor expression |
| Q41472283 | miR-302b inhibits cancer-related inflammation by targeting ERBB4, IRF2 and CXCR4 in esophageal cancer |
| Q64078740 | miRNA and mRNA Integration Network Construction Reveals Novel Key Regulators in Left-Sided and Right-Sided Colon Adenocarcinoma |
Search more.